Journal
CANCER RESEARCH
Volume 74, Issue 15, Pages 4196-4207Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-0582
Keywords
-
Categories
Funding
- NIH/NCI [1R01CA113796, 1R01CA138231, 2P50CA093683, 1R01CA158467]
- U.S. Department of Veterans Affairs (BLR&D VA Merit Award) [10688354]
Ask authors/readers for more resources
The drug efflux transporter ABCB5 identifies cancer stem-like cells (CSC) in diverse human malignancies, where its expression is associated with clinical disease progression and tumor recurrence. ABCB5 confers therapeutic resistance, but other functions in tumorigenesis independent of drug efflux have not been described that might help explain why it is so broadly overexpressed in human cancer. Here we show that in melanoma-initiating cells, ABCB5 controls IL1 beta secretion, which serves to maintain slow cycling, chemoresistant cells through an IL1 beta/IL8/CXCR1 cytokine signaling circuit. This CSC maintenance circuit involved reciprocal paracrine interactions with ABCB5-negative cancer cell populations. ABCB5 blockade induced cellular differentiation, reversed resistance to multiple chemotherapeutic agents, and impaired tumor growth in vivo. Together, our results defined a novel function for ABCB5 in CSC maintenance and tumor growth. (C)2014 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available